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risk factor per se. We compared the respective values of metabolic syndrome
and its components to predict presence of CHD.
 
Methods:
 
 A case control study was conducted in 2001-2004, including 748
cases (French male patients with a history of CHD) and 810 controls from the
general population. Data on medical history and cardiovascular risk factors
were collected. Two logistic regression models were built to predict the prob-
ability to be a case (to have CHD). The first one considered metabolic syn-
drome as explanatory variable. In the second one, metabolic syndrome was
replaced by its components (high blood pressure or antihypertensive drug use,
waist circumference, high glycemia or hypoglycemic drug use, plasma triglyc-
erides and HDL-cholesterol). Both models were adjusted for age, level of edu-
cation, physical activity, smoking and LDL-cholesterol.  
 
Results:
 
 Participants were aged 45-75 years old, 45.4% of cases and 18.6%
of controls had a metabolic syndrome. The sensitivity and the specificity of the
first model to predict CHD were 81% and 62%, respectively, and the c-sta-
tistic reached 0.79 [95% CI: 0.76-0.80]. In the second model, sensitivity, spec-
ificity and c-statistic were 82%, 67% and 0.85 [0.83-0.86], thus leading to a
better discrimination. Among cases, 5.6% were adequately reclassified by the
second model (0.7% non adequately reclassified). Among controls, 16.3%
were adequately reclassified, without any wrong reclassification. Overall, the
second model led to an improved net reclassification of 4.9% in cases and
16.3% in controls, compared to the first model. 
 
Conclusions:
 
 Using the components of the metabolic syndrome in algo-
rithms to predict presence of CHD is better than using metabolic syndrome as
a whole entity. This result should improve the screening of people who are
likely to suffer from silent CHD. 
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Objective: 
 
To compare vascular risk factor profiles and early outcomes in
all French patients hospitalized for either acute coronary (ACS), or cere-
brovascular syndromes (CVS), or both, between 2005 and 2008.
 
Setting:
 
 All French hospitals.
 
Design
 
: Retrospective analysis.
 
Data sources:
 
 National database called “Hospital Discharge Diagnosis
Records”.
 
Main outcomes measured:
 
 Number and annual rates, vascular risk factors,
and early outcome of hospitalized patients for a unique stay for ACS or CVS
or for both ACV and CVS in a 2-month time window.
 
Results: 
 
Over the 4-year study-period, 1,189,043 patients were hospital-
ized for CVS and/or ACS. Among these, 638,061 (53.7%) had CVS alone,
525,419 (44.3%) had ACS alone, and 24,163 (2%) had both. Patients of the
latter group were older (75.2 ± 12 years), and had a higher prevalence of
hypertension (50.8%), diabetes (26.3%), and atrial fibrillation (23.9%)
(p<0.001). In contrast, the prevalence of obesity (9.6%) and hypercholester-
olemia (25.7%) was greater in ACS only patients. Patients with both CVS and
ACS had a longer length of stay (16.1 days), and were less likely to be dis-
charged to home. These patients also had a higher in-hospital risk of death, in
men and in women (Figure). This risk remained after adjustment for age, sex,
and vascular risk factors compared with patients with either CVS alone
(OR=1.71, 95% CI: 1.66-1.77) or ACS alone (OR=2.95, 95% CI: 2.85-3.05).
 
Conclusion: 
 
Our study conducted in almost 1.2 million hospitalized
patients provides clear evidence that patients with both CVS and ACS have a
high vascular risk profile and a marked excess risk of early death.
 
(Voir schémas page suivante)
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Correlation between perceived cardiovascular risk (CVR) by physicians
and real CVR is poorly known. Moreover, the underlying question of factors
associated to risk misevaluation, especially for patients at high CVR and that
could benefit of a lipid lowering therapy (LLT), remains unsolved.
 
Objective and methodology: 
 
This was an on-line non-interventional study
conducted on a sample of 619 general practitioners. The aim was to describe
the relation between physicians evaluated CVR and calculated CVR according
to risk’s scales. All consulting patients’ aged50 years old (YO) were included.
Physicians had to complete a questionnaire and to assess patient’s CVR on a
3 level scale (low, medium, and high). Framingham and SCORE (low
risk<2%, high risk5%) were calculated. 
 
Results: 
 
13446 patients were included (mean age: 67 YO, male: 48%,
LDLc1.3g/L: 46%, LLT: 36%, personal history of CV disease: 16%, smoker:
12%, high blood pressure (HBP): 52%, diabetes: 18%). 
Physicians evaluation mismatched with Framigham for 50% of the patients
and 27% were under-evaluated. Evaluation mismatched with SCORE for 53%
of the patients, 38% were under-evaluated. Within the 25% of the patients
having a Framingham score >20% and without a lipid lowering treatment,
70% was under evaluated by physicians. Within the 38% of the patients
having a SCORE calculation 5% and without a lipid lowering treatment, 78%
were under evaluated.
 
Conclusion: 
 
This study underlines the mismatch between GP perceived
CVR and calculated CVR, especially for high CVR patient. Males, patients
with treated HBP and with high LDL-c were at increased risk of CVR under-
evaluation.
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Objective:
 
 Human immunodeficiency virus (HIV)-infected patients
receiving combined active antiretroviral therapy (cART) are at higher risk of
cardiovascular disease, due in part to metabolic complications such as lipod-
ystrophy syndrome, insulin resistance, and dyslipidemia. Whether lipodys-
trophy and cART impact on the vasculature is debated. We investigated the
impact of lipodystrophy and protease inhibitors (PIs) on aortic stiffness.
 
Methods
 
:
 
 Aortic stiffness was evaluated using carotid–femoral pulse wave
velocity (PWV) in consecutive HIV-infected patients without a history of car-
diovascular disease referred to a cardiovascular clinic.
 
Results:
 
 175 patients were enrolled (mean age 48.2 ± 8.7 years; 89% men).
Eighty six per cent of patients were receiving cART. Dyslipidemia, tobacco,
and hypertension were the most prevalent cardiovascular risk factors (39%,
38%, and 31%, respectively). Seventy-nine (45%) HIV-infected patients had
lipodystrophy and 80 (46%) were on PIs. Aortic PWV was similar in patients
with or without lipodystrophy (9.7±1.9 vs 9.8±2.5 ms
 
-1
 
, respectively; 
 
P
 
 = 0.81)
and in patients on or not on PIs (9.8±2.6 vs 9.7±1.9 ms
 
-1
 
; 
 
P
 
 = 0.71). In
univariate analysis, aortic PWV was associated with increasing age, waist/hip
ratio, systolic and diastolic blood pressures, mean arterial and pulse pressures,
but not with presence of lipodystrophy, PIs, or specific factors related to HIV
infection. Linear regression analysis showed an association between aortic
PWV and age (= 0.49, 
 
P
 
 = 0.001) and systolic arterial pressure (= 0.21, 
 
P
 
 =
0.006).
 
Conclusions:
 
 Aortic stiffness is associated with traditional cardiovascular
risk factors, particularly ageing and blood pressure. Hypertension is becoming
an emerging complication in HIV-infected patients. 
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Objectifve: 
 
To determine the prevalence of hypertension in a cohort of
HIV-infected patients (
 
HIV+).
Methods: 
 
HIV+ patients were enrolled consecutively at ambulatory cardi-
ology consultation.  We evaluated :
cardiovascular risk factors,
office blood pressure,
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Explanatory factors for under-evaluation in primary prevention according to 
SCORE:
 
 OR CI 95%
Treated HBP vs no HBP
 
2,55 2.04-3.19
 
Gender (male)
 
2,44 2,16-2,76
 
Higher LDLc
 
2,13 1,78-2,55
 
Smoker
 
1,82 1,52-2,19
 
Chronic inflammatory disease
 
1,19 1,00-1,42
 
Age
 
1,16 1,15-1,17
